Allergen immunotherapy adverse events in adults with respiratory allergies-data from ADER: An EAACI task force report
Asllani Julijana,Mitsias Dimitrios,Konstantinou George,Qirko Etleva,Hitaj Mirela,Musollari Sybi,Christoff George,Novakova Silviya,Makris Michael,Radulovic Pevec Mira,Pevec Branko,Muntean Adriana,Tomic-Spiric Vesna,Stosovic Rajica,Kosnik Mitja,Mungan Dilsad,Popov A Todor,Calderon Moises,Papadopoulos G Nikolaos,ADER Study Group,Gerta Sinani,Eris Mesonjesi,Esmeralda Shehu,Etleva Qirko,Anila Nano,Valbona Martini,Enkelejda Gjata,Aferdita Sinani,Jana Sinani,Sybi Musollari,Alketa Bakiri,Diana Qama,Erjola Piluri,Fatmira Xhixha,Gilda Xhoxhi,Mirela Hitaj,Mehmet Hoxha,Alfred Priftanji,Dimitrov Zlatko,George Christoff,Silviya Novakova,Katya Noleva,Plamen Yakovliev,Ted Popov,Mirjana Turkalj,Damir Erceg,Asja Stipic,Mira Radulovic Pevec,Branko Pevec,Sanja Popovic,Nikos Papadopoulos,Michalis Makris,George Konstantinou,Dimitris Mitsias,Xenophon Aggelidis,Christina Ciobanum,Ioana Agache,Florin Dan Popescu,Irina Bukur,Ierima Augustin,Deleanu Dianna,Adriana Muntean,Irena Nedelea,Radu Balan,Vesna Tomic-Spiric,Rajica Stosovic,Mirjana Bogic,Dragana Tadic,Alexandra Plavsic,Mitja Kosnik,Zeynep Mısırlıgil,Mungan Dislad,Moises A Z Calderon
DOI: https://doi.org/10.1111/all.16286
IF: 12.4
2024-08-22
Allergy
Abstract:Background: Registries can yield important insights on allergen immunotherapy (AIT) outcomes in daily clinical practice. However, systematic recordings of adverse events (AE) due to AIT in real-life are lacking. Methods: The Allergen Immunotherapy Adverse Events Registry (ADER) is a prospective, multicenter registry on real-life AIT safety. Data on adults (>18 years old) with respiratory allergies receiving AIT with mites, pollens, epithelia, and/or molds were retrieved and analyzed from ADER. The frequency, characteristics and risk factors of AE were investigated. The MedDRA terminology was used to record AE. Results: A total of 1545 individuals with a mean age of 33 ± 10 years receiving 1815 AIT courses (n = 1060 sublingual (SLIT); n = 755 subcutaneous (SCIT)) in centers from eight countries were included. Patients had allergic rhinitis (65%) or, asthma only (3.7%) or rhinitis with asthma (31.2%). Grass was the most frequent specific sensitizer (60.7%), followed by mites (45.5%), birch pollen (20.6%), epithelia (16.1%), and molds (8%). There were 296 AE recorded in 115 patients (7.4%). A higher frequency of AE occurred during up-dosing (59%) compared to maintenance. Severe reactions were rare (0.2%), all in the context of SCIT. After 6 weeks of maintenance only one moderate AE was recorded. The most frequently reported symptoms were from the respiratory system and the skin. Having asthma, doing SCIT, AIT with mugwort, cat, or birch were associated with higher risk for AE while the use of allergoids induced lower risk. Conclusion: In real life clinical practice, AIT-associated AE occur in a minority of patients, while severe reactions are rare. The presence of asthma and use of SCIT are risk factors, while the use of modified allergens lowers the risk.